Early stage non-small cell lung cancer patients with low tumor metabolic activity have longer survival

Low pre-surgery uptake of a labeled glucose analogue, a marker of metabolic activity, in the primary tumor of patients with stage I non-small cell lung cancer is associated with increased overall survival and a longer time before tumor recurrence, a study shows. Patients with high labeled glucose uptake may benefit from additional therapy following surgery. (Mehr in: Cancer News — ScienceDaily)